Of all the uses for hyperbaric oxygen therapy, treatment of diabetic foot ulcers is among the most established — and also among the most over-promised. The honest position sits between the marketing and the dismissal, and two authoritative sources help locate it: the Cochrane systematic review and Medicare’s national coverage policy.
What the Cochrane review found
The Cochrane review Hyperbaric oxygen therapy for chronic wounds (Kranke and colleagues, updated June 2015) pooled ten trials involving 531 participants with diabetic foot ulcers. Its central finding was a genuine but limited signal: across five trials with 205 participants, HBOT increased the chance of ulcer healing at six weeks, with a risk ratio of 2.35.
The important caveat comes immediately after. That benefit “was not evident at longer-term follow-up at one year.” In other words, the wounds that healed faster with HBOT were not necessarily more likely to stay healed once the clock ran out.
On the outcome patients care about most — avoiding amputation — the review could not confirm a benefit. Across five trials and 312 participants, the reduction in major amputation rate was not statistically significant. And the reviewers were candid about the quality of the underlying research, noting the trials “had various flaws in design and/or reporting” and that they could not even properly assess safety because none of the included trials reported major adverse events.
How Medicare draws the line
U.S. payer policy mirrors that caution. Medicare’s National Coverage Determination 20.29 covers hyperbaric oxygen for diabetic lower-extremity wounds only when three conditions are all met: the patient has type I or type II diabetes with a lower-extremity wound caused by diabetes; the wound is classified as Wagner grade III or higher; and the patient has failed an adequate course of standard wound therapy.
The policy goes further. HBOT is covered as an adjunctive therapy only after there have been no measurable signs of healing for at least 30 consecutive days of standard treatment, and continued HBOT is not covered if measurable healing isn’t demonstrated within a 30-day period. NCD 20.29 also explicitly excludes ordinary cutaneous, decubitus, and stasis ulcers, as well as chronic peripheral vascular insufficiency, from coverage.
That structure tells you how Medicare reads the evidence: hyperbaric oxygen is a last-line adjunct for advanced, non-healing wounds — not a first move, and not a substitute for the fundamentals.
The adjunct, not the answer
It is worth stressing what HBOT is added to. Effective diabetic-wound care rests on debridement, offloading pressure from the wound, glucose control, correcting blood flow, and managing infection. Hyperbaric oxygen, where indicated, supplements that work; it does not replace it.
The balanced takeaway
Hyperbaric chambers are FDA-cleared devices, but “diabetic foot ulcer” is not a blanket green light, and the FDA has warned that HBOT is widely promoted for conditions where benefit is unproven. The defensible reading of the evidence is this: for advanced diabetic foot ulcers that have failed optimized standard care, HBOT offers a short-term healing benefit that the best review found real but not durable at one year, with no confirmed reduction in amputations and trial quality that leaves real uncertainty. That is a reasonable adjunct for the right patient — and a poor fit for the sweeping claims often attached to it.
Sources
- Cochrane — Hyperbaric oxygen therapy for treating chronic wounds (plain-language summary)
- PubMed — Kranke et al., Hyperbaric oxygen therapy for chronic wounds (2015)
- CMS — NCD 20.29 Hyperbaric Oxygen Therapy (Medicare Coverage Database)
- Noridian (Medicare contractor) — HBOT for Diabetic Wounds, NCD 20.29 guidance